Jamjoom Pharmaceuticals Factory Company (TADAWUL:4015)

Market Cap	10.87B -1.0%
Revenue (ttm)	1.50B +13.8%
Net Income	463.80M +30.1%
EPS	6.63 +30.1%
Shares Out	70.00M
PE Ratio	23.44
Forward PE	n/a
Dividend	4.00 (2.58%)
Ex-Dividend Date	Mar 2, 2026

Volume	57,314
Average Volume	44,580
Open	154.00
Previous Close	155.30
Day's Range	154.00 - 155.50
52-Week Range	125.00 - 183.80
Beta	0.33
RSI	63.87
Earnings Date	May 7, 2026

About TADAWUL:4015

Jamjoom Pharmaceuticals Factory Company, together with its subsidiaries, engages in the manufacture and distribution of pharmaceutical and consumer products in the Kingdom of Saudi Arabia, Gulf, Iraq, Egypt, North Africa, and internationally. It provides human medicines; nutraceuticals; antibiotics; general analgesics; medicines for treatment of cough, allergy, asthma, heart diseases, blood pressure, diarrhea, vomiting, and ulcer and acidity; treatment of various skin infections and cancer diseases; and eye drops, and ointments and cosmeceutica...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Country: Saudi Arabia
• Stock Exchange: Saudi Stock Exchange
• Ticker Symbol: 4015

Financial Performance

In 2025, TADAWUL:4015's revenue was 1.50 billion, an increase of 13.82% compared to the previous year's 1.32 billion. Earnings were 463.80 million, an increase of 30.09%.